{
}
Barclays has maintained an 'Overweight' rating for Sanofi, noting the company's positive trajectory into FY25. As the largest European pharmaceutical group, Sanofi's net sales are primarily driven by pharmaceutical products (79.8%), with a focus on specialty and general medicine, alongside human vaccines (20.2%). The company operates 52 production sites globally, with significant sales in the U.S. (48.7%) and Europe (22%).
Barclays has expressed strong confidence in Sanofi, maintaining an 'overweight' rating and setting a price target of 125 euros, anticipating group net sales of 9.61 billion euros for Q1 2025. The optimism is fueled by Sanofi's direct-to-consumer campaign for Dupixent targeting COPD and upcoming product launches, which are expected to enhance market momentum. Sanofi's strategic vaccination approach and regulatory navigation further underscore its commitment to stable growth.
Sanofi shares are poised for a breakout, currently testing resistance at EUR 106.66, with a target of EUR 137.00 if the price surpasses EUR 110.00. Analysts largely recommend buying, with an average target of EUR 117.77, and the stock benefits from a favorable seasonal trend, historically rising 8.3% until the end of May.
UBS has named Roche as its preferred Swiss pharmaceutical stock, upgrading its rating to "Buy" and raising the target price from CHF 300 to CHF 338. The firm cites Roche's sustainable growth, driven by strong performances from Vabysmo and Ocrevus, and anticipates significant sales increases from ongoing development projects, including Ocrevus HD and Trontinemab. While Roche's earnings per share growth is projected at 8.1% from 2024 to 2029, slightly below the industry average, UBS remains optimistic about the company's long-term potential and cash flow for acquisitions.
UBS has upgraded SANOFI to a 'Buy' rating, indicating a positive outlook for the stock. However, the information provided is for informational purposes only and does not constitute a recommendation to buy or sell. Investors are reminded of the risks involved in purchasing securities, which may lead to total capital loss.
UBS has maintained a "Buy" rating for Sanofi, setting a target price of 120 euros. Analyst Jo Walton highlighted that the future of Sanofi's immunology products will be influenced by the discussion surrounding copycat drugs for Dupixent expected around 2030, countering skepticism about their medical applications.
Sanofi, Europe's leading pharmaceutical group, generates 70.6% of its sales from pharmaceutical products, with specialty medicine accounting for 59.3%. The company also focuses on human vaccines (17.4%) and consumer healthcare products (12%). By the end of 2023, Sanofi will operate 54 production sites globally, with significant sales in the United States (43%) and Europe (18.6%).
UBS has maintained a 'Buy' rating for Sanofi, setting a target price of 120 euros. Analyst Jo Walton highlighted that the future of Sanofi's immunology products will be influenced by the discussion surrounding copycat drugs for Dupixent expected around 2030, countering skepticism about their medical applications.
UBS has upgraded SANOFI to a 'Buy' rating, indicating a positive outlook for the stock. However, the information provided is for informational purposes only and does not constitute a recommendation to buy or sell securities. Investors are reminded of the risks involved, including the potential total loss of capital.
UBS has maintained a 'Buy' rating for Sanofi, setting a target price of 120 euros. Analyst Jo Walton expressed optimism regarding the upcoming launches of Dupixent for COPD and Tolebrutinib for smoldering MS following a recent management call.
Sanofi
Companies
| Symbol | SNY |
| Name | Sanofi |
| Currency | USD |
| Sector | Health Care |
| IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences |
| Industry | Pharmaceuticals |
| Market | NASDAQ Global Select |
| Country | France |
| State | |
| City | Paris |
| Zipcode | 75008 |
| Website | http://www.sanofi.com |
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
barclays maintains overweight rating on sanofi as it progresses into fy25
16:41 01.04.2025
barclays optimistic on sanofi's growth ahead of 2025 market targets
15:52 01.04.2025
Sanofi shares poised for breakout amid favorable analyst outlook and seasonality
14:40 18.03.2025
ubs upgrades roche to preferred pharmaceutical stock with strong growth potential
United States Dollar
Euro
Swiss Franc
Nestlé S.A.
Sanofi
Hoffmann-La Roche AG
Novartis AG
CHE
Show more
12:00 13.02.2025
ubs upgrades sanofi to buy amid investment considerations and risks
09:58 13.02.2025
ubs maintains buy rating for sanofi with target price of 120 euros
09:58 13.02.2025
sanofi maintains strong market position with diverse pharmaceutical and vaccine offerings
09:46 13.02.2025
ubs maintains buy rating for sanofi with target price of 120 euros
09:46 13.02.2025
ubs upgrades sanofi to buy amid investment considerations and risks
12:48 03.02.2025
UBS maintains buy rating for Sanofi with target price of 120 euros
12:48 03.02.2025
Trending
Subcategory
Corporate News
Industry Trends
Stock Market Updates
Industry Mergers & Acquisitions
Banking Regulations
Workplace Trends
Finance Mergers & Acquisitions
Global Financial Events
Retail and Consumer Goods
CEO Changes
Market Analysis and Predictions
Central Bank Actions
Startups & Entrepreneurship
Global Trade Developments
Government Policies
Financial Scams and Security
Domestic Politics
Private Equity Deals
Government Economic Policies
Supply Chain Management
Countries:
Companies:
JPMorgan Chase & Co.
Tesla, Inc.
Barclays PLC
Credit Suisse Lux Digital Healt
Bank of America Corporation
UniCredit S.p.A.
Deutsche Bank Money Market PP
The Goldman Sachs Group, Inc.
UBS Group AG
Banco BPM S.p.A.
Apple Inc.
BNP Paribas SA
Wells Fargo & Company
Commerzbank AG
Banco Santander, S.A.
CREDIT AGRICOLE
Lloyds Banking Group plc
SpaceXCoin USD
Morgan Stanley
Credit Suisse Strategic Income I
Currencies:
United States Dollar
Euro
British Pound Sterling
Swiss Franc
Chinese Yuan
Indian Rupee
Japanese Yen
South Korean Won
Danish Krone
Hong Kong Dollar
Australian Dollar
Singapore Dollar
Offshore Chinese Yuan
Mexican Peso
Russian Ruble
Chilean Peso
Canadian Dollar
United Arab Emirates Dirham
Norwegian Krone
Swedish Krona
People: